Nonalcoholic fatty liver disease: Clinical features and pathogenesis

Gastroenterology and Hepatology

Volumn 2, Issue 4, 2006, Pages 282-291

  Basaranoglu, Metin ^a   Neuschwander Tetri, Brent A ^b,c  

^a SELCUK UNIVERSITY   (Turkey)

^b Saint Louis University   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ballooning of hepatocytes; Insulin resistance; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTIFIBROTIC AGENT; BETAINE; CARNITINE; CHOLINE; CYTOKINE ANTIBODY; ENDOTOXIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; S ADENOSYLMETHIONINE; SELENIUM; SILYMARIN; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EXERCISE; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PREVALENCE; REVIEW; STEATOSIS; WEIGHT REDUCTION;

EID: 33846135797     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419.
2. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664-669.
3. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000;32:689-692.
4. Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl. 2001;7:797-801.
5. Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl. 2001;7:608-614.
6. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485-1493.
7. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of non-alcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134-140.
8. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:527-534.
9. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of non-alcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132-138.
10. Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol. 2002;97:2058-2062.
11. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Sem Liver Dis. 2001;21:17-26.
12. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960-967.
13. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124:71-79.
14. Sorensen TI, Orholm M, Bentsen KD, Hoybye G, Eghoje K, Christoffersen P. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet. 1984;2:241-244.
15. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003;124:97-104.
16. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40:820-826.
17. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology. 2003;124:248-250.
18. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450-455.
19. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844-1850.
20. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001;21:27-41.
21. Seppälä-Lindroos A, Vehkavaara S, Häkkinen A-M, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endo Metab. 2002;87:3023-3028.
22. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367-372.
23. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-923.
24. Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis. 2004;36:165-173.
25. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33:283-303.
26. Evans CDJ, Oien KA, MacSween RNM, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol. 2002;55:689-692.
27. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic ratty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98:2042-2047.
28. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3-16.
29. Brunt EM, Ramrahkiani S, Cordes BG, et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol. 2003;16:49-56.
30. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage: the Dionysos Study Group. Gut. 1997;41:845-850.
31. Kim WR, Brown RS, Jr., Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227-242.
32. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol. 2005;288:E462-468.
33. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med. 1988;27:142-149.
34. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology. 1994;20:1442-1449.
35. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1-9.
36. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42:44-52.
37. Fan J-G, Zhu J, Li X-J, et at. Prevalence of and risk factors for ratty liver in a general population of Shanghai, China. J Hepatol 2005;43:508-514.
38. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol. 2005;19:3-23.
39. Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. Is NASH underdiagnosed among African Americans? Am J Gastroenterol. 2002;97:1496-1500.
40. Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol. 2004;99:292-298.
41. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol. 1999;94:3010-3014.
42. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117-1123.
43. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol. 2001;35:195-199.
44. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci. 2005;329:111-116.
45. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12:1106-1110.
46. Sanyal AJ, Campbell-Sargent C, Mirshani F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183-1192.
47. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373-379.
48. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
49. Formiguera X, Cantón A. Obesity: epidemiology and clinical aspects. Baillieres Best Pract Res Clin Gastroenterol. 2004;18:1125-1146.
50. Andersen T, Christoffersen P, Gluud C. The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. Int J Obes. 1984;8:107-115.
51. Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci. 1995;40:2002-2009.
52. Sanyal A. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;1213:1705-1725.
53. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Related Metab Disord. 1998;22:222-226.
54. García-Monzón C, Martín-Pérez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol. 2000;33:716-724.
55. Ong JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15:310-315.
56. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr. 1995;127:700-704.
57. Noguchi H, Tazawa Y, Nishinomiya F, Takada G. The relationship between serum transaminase activities and fatty liver in children with simple obesity. Acta Paediatrica Japonica. 1995;37:621-625.
58. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2000;30:48-53.
59. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103-1109.
60. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45:1929-1934.
61. Steiner G. Hyperinsulinaemia and hypertriglyceridaemia. J Intern Med Supplement. 1994;736:23-26.
62. Day CP, James OF. Steatohepatitis; a tale of two "hits"? Gastroenterology. 1998;114:842-845.
63. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202-1219.
64. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201-229.
65. Haque M, Sanyal AJ. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Baillieres Best Pract Res Clin Gastroenterol 2002;16:709-731.
66. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147-152.
67. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343-1351.
68. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48:634-642.
69. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci. 1997;94:2557-2562.
70. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol. 2005;42;928-940.
71. Crespo J, Cayón A, Fernández-Gil P, et al. Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001;34:1158-1163.
72. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology. 2002;36:403-409.
73. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8:731-737.
74. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91-100.
75. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology. 2004;40:46-54.
76. Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease seventy. J Clin Endo Metab. 2005;90:3498-3504.
77. Haussinger D, Lang F. Cell volume in the regulation of hepatic function: a mechanism for metabolic control. Biochem Biophys Acta. 1991;1071:331-350.
78. McManus ML, Churchwell KB, Strange K. Regulation of cell volume in health and disease. N Engl J Med. 1995;333:1260-1266.
79. Lang F, Lepple-Wienhues A, Paulmichl M, Szabo I, Siemen D, Gulbins E. Ion channels, cell volume, and apoptotic cell death. Cell Physiol Biochem. 1998;8:285-292.
80. Dunkelberg JC, Feranchak AP, Fitz JG. Liver cell volume regulation: size matters. Hepatology. 2001;33:1349-1352.
81. Minton AP. The influence of macromolecular crowding and macromolecular confinement on biochemical reactions in physiological media. J Biol Chem. 2001;276:10577-10580.
82. Del Monte U. Swelling of hepatocytes injured by oxidative stress suggests pathological changes related to macromolecular crowding. Med Hypotheses. 2005;64:818-825.
83. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94:1018-1022.
84. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286-1292.
85. Turlin B, Mendier MH, Moirand R, Guyader D, Guillygomarc'h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload: a study of 139 patients. Am J Clin Pathol 2001;116:263-270.
86. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39:179-187.
87. Jacobs JE, Birnbaum BA, Shapiro MA, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. Am J Roentgenology. 1998;171:659-664.
88. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710-723.
89. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122:1649-1657.
90. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745-750.
91. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395.
92. Thomas EL, Hamilton G, Patel N, et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut. 2005;54:122-127.
93. Brunt EM, Janney CJ, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: A proposal for grading and staging the histologic lesions. Am J Gastroenterol. 1999;94:2467-2474.
94. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
95. Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol. 2004;35:196-199.
96. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74-80.
97. Ayata G, Gordon FD, Lewis WD, et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol. 2002;33:1098-1104.
98. Hui JM, Kench J, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38:420-427.
99. Chapman RW. To perform or not to perform liver biopsy-that is the question. Gut. 2002;51:9-10.
100. Sorrentino P, Tarantino G, Conca P, et al. Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol. 2004;41:751-757.
101. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic ratty liver: a follow-up study. Hepatology. 1995;22:1714-1719.
102. Dam-Larsen S, Franzmann M-B, Christoffersen P, Larsen K, Becker U, Bendtsen F. Histological characteristics and prognosis in patients with fatty liver. Scand J Gastro. 2005;40:460-467.
103. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113-121.
104. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990;99:1408-1413.
105. Bugianesi E, Marzocchi R, Villanova N, Marchesini G. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Baillieres Best Pract Res Clin Gastroenterol. 2004;18:1105-1116.
106. Mendes FD, Lindor KD. Recent advances in the treatment of non-alcoholic fatty liver disease. Expert Opinion on Investigational Drugs. 2005;14:29-35.
107. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770-778.
108. Zelman S. The liver in obesity. Arch Intern Med. 1952;90:141-156.
109. Lombardi B. Considerations on the pathogenesis of fatty liver. Lab Invest. 1966;15:1-20.
110. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proc. 1980;55:434-438.
111. Harrison SA, Neuschwander-Tetri BA. Pharmacologic management of non-alcoholic fatty liver disease. Clin Lin Dis. 2004;8:715-728.